Patents Assigned to Yamanouchi Pharmaceutical Co., Ltd.
  • Patent number: 7989634
    Abstract: The present invention relates a compound of formula 1, and pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: August 2, 2011
    Assignees: LG Life Sciences Ltd., Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Koo Lee, Heui-Sul Park, In-Ae Ahn, Hyun-Ju Yoo, Jong-Yup Kim, Deog-Young Choi, Hyeon-Joo Yim, Kyung-Ha Chung, Dong-Sup Shim, Sang-Kyun Lee, Yutaka Kondoh, Ryoji Hirabayashi, Shugo Honda, Hidetaka Kaku, Jun-ichi Shishikura, Hiroyuki Ito, Takeshi Kurama
  • Patent number: 7794748
    Abstract: This invention is aimed to provide a stabilized formulation of ramosetron or a pharmaceutically acceptable salt thereof under a temperature/humidity condition, especially at a low content and relates to a stable oral solid drug composition of ramosetron or a pharmaceutically acceptable salt thereof, which is characterized by containing one or two or more members selected from the group consisting of an aliphatic carboxylic acid or an ester thereof, a hydroxycarboxylic acid or an ester thereof, an acidic amino acid, an enolic acid, an aromatic carboxyl compound or an ester thereof, and a carboxyl group-containing high-molecular substance, and to a stabilization method of the same. Also, this invention relates to a therapeutic agent of diarrhea-predominant irritable bowel syndrome containing from 0.002 to 0.02 mg of ramosetron hydrochloride as a daily dose or an equivalent molar amount of ramosetron or its pharmaceutically acceptable other salt as an active ingredient.
    Type: Grant
    Filed: August 27, 2004
    Date of Patent: September 14, 2010
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Akio Sugihara, Katsuhiro Masaki, Takehiko Yasuji
  • Patent number: 7268150
    Abstract: Provided is a compound having excellent dipeptidyl peptidase IV-inhibiting activity, and a remedy based on the activity for insulin-dependent diabetes (type 1 diabetes), especially for non insulin-dependent diabetes (type 2 diabetes), insulin-resistant disorders, and obesity.
    Type: Grant
    Filed: July 18, 2003
    Date of Patent: September 11, 2007
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Masahiko Hayakawa, Kenji Negoro, Satoshi Miyamoto, Takayuki Suzuki, Tatsuya Maruyama, Ryosuke Nakano
  • Publication number: 20070129346
    Abstract: The present invention relates a compound of formula 1, and pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.
    Type: Application
    Filed: November 12, 2004
    Publication date: June 7, 2007
    Applicants: LG Life Sciences Ltd., Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Koo Lee, Heui-Sul Park, In-Ae Ahn, Hyun-Ju Yoo, Jong-Yup Kim, Deog-Young Choi, Hyeon-Joo Yim, Kyung-Ha Chung, Dong-Sup Shim, Sang-Kyun Lee, Yutaka Kondoh, Ryoji Hirabayashi, Shugo Honda, Hidetaka Kaku, Jun-ichi Shishikura, Hiroyuki Ito, Takeshi Kurama
  • Publication number: 20060276545
    Abstract: Polyhydroxy phenols, which are non-peptidic mimetics of galloyl peptides, and a process for the preparation of gallic acid derivatives using a gallic-acid providing moiety are provided as well as polyhydroxy phenol-containing pharmaceutical and nutraceutical compositions. The use of polyhydroxy phenols as a medicament and especially for the manufacture of a medicament for the prevention, treatment or diagnosis of a disease or a condition, wherein P-selectin is involved, is provided. The same compounds can also be used as targeting tools to P-selectin expressing cells or tissues in a composition, further comprising an active compound in a vehicle.
    Type: Application
    Filed: May 7, 2004
    Publication date: December 7, 2006
    Applicant: YAMANOUCHI PHARMACEUTICAL CO., LTD.
    Inventors: Erik Anna Biessen, Chantal Appeldoorn, Arnaud Bonnefoy, Theodorus Van Berkel, Johan Kuiper, Marc Hoylaerts
  • Publication number: 20060069130
    Abstract: Obtaining the crystal of 4,6-dimethyl-4?-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]nicotinanilide having excellent activity of inhibiting Ca2+ release-activated Ca2+ channel and suppressing IL-2 production to find that the compound includes the presence of two types of polymorphic crystals and that any of the crystals is preferable as a raw material for producing pharmaceutical compositions.
    Type: Application
    Filed: August 26, 2003
    Publication date: March 30, 2006
    Applicant: YAMANOUCHI PHARMACEUTICAL CO., LTD.
    Inventors: Hirokazu Kubota, Kiyoshi Iwaoka, Sou Yamaguchi, Masaki Yokota
  • Patent number: 7008640
    Abstract: The present invention presents a pharmaceutical composition for oral use with improved absorption, which comprises drug, aminoalkyl methacrylate copolymer E, and acidic substance and is obtained by bringing said 3 components together and uniformly mixing at least this polymer and this acidic substance, and a method of improving oral absorption by using this pharmaceutical composition. Moreover, the present invention presents an agent for improving oral absorption that increases drug permeability of the digestive tract mucous membrane and/or mucous layer present on the surface of this membrane, whose active ingredient is aminoalkyl methacrylate copolymer E. In addition, the present invention presents an oral agent for improving absorption by increasing drug permeability of the digestive tract mucous membrane and/or the mucous layer distributed over this mucous membrane, whose effective component is aminoalkyl methacrylate copolymer E.
    Type: Grant
    Filed: July 16, 2001
    Date of Patent: March 7, 2006
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Shunsuke Watanabe, Shigeo Takemura, Yuuki Tsutsui, Hiromu Kondo, Kiyo Nakanishi, Kazuhiro Sako, Toyohiro Sawada
  • Patent number: 6960591
    Abstract: Provided is a pharmaceutical composition containing a propane-1,3-dione derivative as the active ingredient, particularly a GnRH receptor antagonist. Also, provided is a propane-1,3-dione derivative having a GnRH antagonistic effect.
    Type: Grant
    Filed: July 4, 2001
    Date of Patent: November 1, 2005
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Masaaki Hirano, Eiji Kawaminami, Akira Toyoshima, Hiroyuki Moritomo, Norio Seki, Ryutaro Wakayama, Minoru Okada, Toshiyuki Kusayama
  • Publication number: 20050233304
    Abstract: A screening tool and a convenient screening method for obtaining a renal failure treating agent, and a pharmaceutical composition for treating renal failure and a production method thereof are disclosed. The aforementioned screening tool is a G protein coupling type receptor FGK which is a polypeptide capable of activating CTGF promoter, a functionally equivalent modified substance thereof or a homologous polypeptide, or a cell expressing the aforementioned polypeptide. The screening method is a method which employs inhibition of the aforementioned polypeptide as the index.
    Type: Application
    Filed: October 9, 2003
    Publication date: October 20, 2005
    Applicant: YAMANOUCHI PHARMACEUTICAL CO., LTD.
    Inventors: Kentaro Enjo, Sadao Kuromitsu
  • Patent number: 6949543
    Abstract: The invention relates to a novel amide derivative which is an N-({[4-(substituted thiazol-4-yl)phenyl]carbamoyl}methyl)amide derivative having a characteristic in that an aryl or heteroaryl group as an aromatic ring group is directly substituted on the N atom of amido group. Since said amide derivative has excellent anti-herpesvirus action, it is useful as medicaments and antiviral agents, particularly as preventive or therapeutic agents for various diseases accompanied by Herpesviridae virus infections, illustratively, varicella (chickenpox) accompanied by varicella zoster virus infection, shingles accompanied by the recurrent infection of latent varicella zoster virus, labial herpes and herpes encephalitis accompanied by HSV-1 infection, genital herpes accompanied by HSV-2 and the like various herpesvirus infections.
    Type: Grant
    Filed: November 8, 2001
    Date of Patent: September 27, 2005
    Assignees: Yamanouchi Pharmaceutical Co., Ltd., Rational Drug Design Laboratories
    Inventors: Toru Kontani, Junji Miyata, Wataru Hamaguchi, Yoji Miyazaki, Hiroshi Suzuki, Eiichi Nakai, Shunji Kageyama
  • Publication number: 20050209134
    Abstract: The present invention relates to a novel compound which is useful as an agent for prevention and treatment of diseases associated with HDAC, in particular, tumor or cell proliferative diseases. The depsipeptide compound or its pharmaceutically acceptable salt of the present invention has a good HDAC inhibitory activity and an inhibitory activity of cell proliferation against human cancer cells and, therefore, is useful in treatment and improvement of diseases and pathogenic conditions associated with histone acetylation, in particular, tumor or cell proliferative diseases.
    Type: Application
    Filed: August 28, 2003
    Publication date: September 22, 2005
    Applicant: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Koji Nagai, Masatoshi Taniguchi, Nobuaki Shindo, Yoh Terada, Masamichi Mori, Nobuaki Amino, Ken-ichi Suzumura, Isao Takahashi, Mitsuo Amase
  • Publication number: 20050192329
    Abstract: A therapeutic method and pharmaceutical compositions for treatment of irritable bowel syndrome including non-constipated irritable bowel syndrome such as diarrhea-predominant irritable bowel syndrome and alternating constipation/diarrhea irritable bowel syndrome in male and female patients, which may comprise administering a patient with from 0.001 to 0.05 mg of ramosetron hydrochloride as a daily dose or an equivalent molar amount of ramosetron or its pharmaceutically acceptable other salt.
    Type: Application
    Filed: January 28, 2005
    Publication date: September 1, 2005
    Applicant: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Akito Nishida, Akira Niwa, Yutaka Atsuta
  • Publication number: 20050175689
    Abstract: The present invention makes it possible to provide drug-containing coated microparticles for quick-disintegrating oral tablets wherein microparticles containing a drug with an unpleasant taste are coated with a film composed of (1) a pH-independent water-insoluble polymer accounting for 60% or more but less than 80% of the film and (2) a pH-independent water-soluble substance accounting for more than 20% to 40% or less of the film, these microparticles being characterized in that the rate of dissolution of the drug from the drug-containing microparticles is 0% to 10% in one minute and 80% to 100% in 30 minutes, and the average particle diameter is 350 ?m or less, in order to realize sufficient control of oral drug dissolution and fast gastrointestinal drug dissolution.
    Type: Application
    Filed: October 27, 2004
    Publication date: August 11, 2005
    Applicant: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Ippei Kurimoto, Yuki Kasashima, Hitoshi Kawai, Yuuki Takaishi, Masataka Katsuma, Hiroshi Ohi, Takayuki Yoshida, Hiroaki Tasaki
  • Patent number: 6927233
    Abstract: Compositions and methods for controlling intraocular pressure and treating glaucoma using 1-(2-aminopropyl)-indazol-6-ol are disclosed.
    Type: Grant
    Filed: November 14, 2000
    Date of Patent: August 9, 2005
    Assignees: Alcon, Inc., Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Jesse A. May, Anura P. Dantanarayana
  • Publication number: 20050163840
    Abstract: The present invention is a system for averting undesirable pharmacokinetic drug interaction between a drug and concomitant drug(s), which consists of controlling the in vivo release time and/or release site of the drug and/or the concomitant drug.
    Type: Application
    Filed: June 10, 2004
    Publication date: July 28, 2005
    Applicant: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Toyohiro Sawada, Kazuhiro Sako, Tatsunobu Yoshioka, Shunsuke Watanabe
  • Patent number: 6919372
    Abstract: The present invention relates to sustained-release pharmaceutical compositions for ionic pharmaceutically active substances containing ionic compounds having opposite charges to those of ionic prostanoic acid derivatives and increasing hydrophobicity of the active substances. More specifically, the invention relates to sustained-release pharmaceutical compositions comprising the ionic prostanoic acid derivatives and the ionic compounds having opposite charges to those of the prostanoic acid derivatives and increasing hydrophobicity of these derivatives that contain hydrophobic groups in the molecule thereof. The pharmaceutical composition of the invention can exhibit excellent sustained release effect of the ionic prostanoic acid derivatives, irrespective of water solubility possessed by the ionic prostanoic acid derivatives.
    Type: Grant
    Filed: December 25, 1998
    Date of Patent: July 19, 2005
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Noboru Yamashita, Akira Takagi, Masataka Katsuma, Katsumi Saito, Yuuki Takaishi, Tatsuo Yasuda, Yutaka Takahashi, Mitsuo Mitomi, Michio Hara
  • Patent number: 6903125
    Abstract: A pharmaceutical drug, particularly a novel compound useful for the prophylaxis or therapeutic treatment of various diseases involving infections with viruses of the Herpesviridae family, specifically various herpesvirus infections such as varicella (chicken pox) via varicella zoster virus, varicella zoster via recurrent infection with latent varicella zoster virus, herpes labialis and herpes encephalitis via HSV-1 and genital herpes via HSV-2 infection. N-{2-[(4-Substituted phenyl)amino]-2-oxoethyl}tetrahydro-2H-thiopyran-4-carboxamide derivative where the phenyl group is substituted at position 4 with a specific five-membered or 6-membered heteroaryl group, has such great anti-virus activity that the oral dosing thereof at a low dose enabled the therapeutic treatment of the diseases.
    Type: Grant
    Filed: August 6, 2004
    Date of Patent: June 7, 2005
    Assignees: Yamanouchi Pharmaceutical Co., Ltd., Rational Drug Design Laboratories
    Inventors: Toru Kontani, Junji Miyata, Wataru Hamaguchi, Tomoaki Kawano, Akio Kamikawa, Hiroshi Suzuki, Kenji Sudo
  • Patent number: 6899899
    Abstract: The present invention relates to a pharmaceutical composition useful for rapid disintegration, which comprises a sparingly soluble medicament held on a gel-forming water-soluble polymer as a solid dispersion, wherein it contains a salt substance that comprises an alkali and a weak or strong acid and has an endothermic standard enthalpy of solution or heat of solution. Since rapid disintegration of the pharmaceutical composition of the present invention and rapid dissolution of the medicament contained in the preparation can be made in the digestive tracts pH-independently, good bioavailability can be attained.
    Type: Grant
    Filed: July 9, 2002
    Date of Patent: May 31, 2005
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Hirokazu Takagi, Atsushi Kajiyama, Masahiro Yanagisawa
  • Publication number: 20050112206
    Abstract: The present invention presents a pharmaceutical composition for oral use with improved absorption, which comprises drug, aminoalkyl methacrylate copolymer E, and acidic substance and is obtained by bringing said 3 components together and uniformly mixing at least this polymer and this acidic substance, and a method of improving oral absorption/by using this pharmaceutical composition. Moreover, the present invention presents an agent for improving oral absorption that increases drug permeability of the digestive tract mucous membrane and/or mucous layer present on the surface of this membrane, whose active ingredient is aminoalkyl methacrylate copolymer E. In addition, the present invention presents an oral agent for improving absorption by increasing drug permeability of the digestive tract mucous membrane and/or the mucous layer distributed over this mucous membrane, whose effective component is aminoalkyl methacrylate copolymer E.
    Type: Application
    Filed: September 10, 2004
    Publication date: May 26, 2005
    Applicant: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Shunsuke Watanabe, Shigeo Takemura, Yuuki Tsutsui, Himoru Kondo, Kiyo Nakanishi, Kazuhiro Sako, Toyohiro Sawada
  • Publication number: 20050100603
    Abstract: [Problem] As compared with the current oral sustained-release preparation containing tamsulosin hydrochloride which have been supplied to the medical setting at present, it is needed to provide a sustained-release pharmaceutical composition in which the efficacy is equivalent or even better, adverse events such as adverse reactions (e.g., postural hypotension) are reduced, dose can be increased and, if desired, ingestion of food is not limited in the dosage and it is also needed to provide a method for administration of tamsulosin hydrochloride in which the adverse reactions accompanied by therapy or prevention on the basis of an ?1 receptor blocking action are reduced.
    Type: Application
    Filed: May 10, 2004
    Publication date: May 12, 2005
    Applicant: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Kazuhiro Sako, Toyohiro Sawada, Hiromu Kondo, Keiichi Yoshihara, Hiroyuki Kojima